Johns Hopkins Drug Discovery - Takashi Tsukamoto

wp-singular,page-template,page-template-full_width,page-template-full_width-php,page,page-id-811,page-child,parent-pageid-41,wp-theme-bridge,bridge-core-3.0.5,qi-blocks-1.0.6,qodef-gutenberg--no-touch,qodef-qi--no-touch,qi-addons-for-elementor-1.5.5,qode-page-transition-enabled,ajax_fade,page_not_loaded,,qode-theme-ver-29.1,qode-theme-bridge,disabled_footer_bottom,wpb-js-composer js-comp-ver-6.9.0,vc_responsive,elementor-default,elementor-kit-3247,x-shortcodes-v3_0_5

Takashi Tsukamoto

Takashi Tsukamoto, Ph.D.

Director, Medicinal Chemistry

Rangos 231

410-614-0982

[email protected]

Takashi Tsukamoto, Ph.D., is a Professor of Neurology and Pharmacology in the School of Medicine and serves as the Director of Medicinal Chemistry at Johns Hopkins Drug Discovery. Prior to joining Johns Hopkins in 2009, Dr. Tsukamoto held positions of increasing responsibility at Guilford Pharmaceuticals, MGI Pharma, and the Eisai Research Institute. He has served as a lead medicinal chemist on several drug discovery projects, developing new therapeutics for neurological disorders and cancer. Dr. Tsukamoto is the lead inventor of the cytidine deaminase inhibitor cedazuridine and its oral combination with decitabine, which received FDA approval as Inqovi in 2020 for the treatment of myelodysplastic syndromes. At Johns Hopkins Drug Discovery, Dr. Tsukamoto leads a team of medicinal chemists focused on the design and synthesis of small molecules with therapeutic potential in various disease areas.

Takashi Tsukamoto